Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2002

View Archived Issues

Marketing application filed in E.U. for Axcan's photodynamic therapy

Chymase inhibition in the spotlight

The role of endothelin blockade in organ transplantation

Studies on immunosuppression with FK-778 a highlight at Transplant 2002

Cellegy withdraws Cellegesic NDA

Lexicon Genetics discovers new oncogene for development of anticancer drugs

FDA alerts to Actos and Avandia label modifications

Transplant 2002: IDEC-131 improves transplant graft survival in combination regimens

Chinese herbal medicine improves I/R injury to the kidney via activation of eNOS

Drug used for xerostomia may help prevent lung cancer

Combination of antimetabolite and thymidine phosphorylase inhibitor in clinical development at Taiho

New selective partial agonist at D4 receptors designed at German university

Dihydropyridine Y1 receptor antagonists reduce food intake in rat models

LY-402913, a selective MRP1 inhibitor with in vivo resistance-modulating activity

Orally active thrombin inhibitor advances to phase II clinical trials at Boehringer Ingelheim

Aventis and Fujisawa form alliance for marketing of Synercid

Genta and Aventis collaborate on Genasense development and commercialization

Hyseq collaborations mark first quarter

DiAthegen and TissueInformatics form obesity and type 2 diabetes joint venture

Antex Biologics presents pipeline development plans

Neotrofin fails to meet primary endpoint in Alzheimer's disease

Selective estrogens with preference for the ERalpha receptor claimed by Jenapharm

Pharmacor presents new anti-HIV agents

Enantiomerically pure antiarrhythmic compounds prepared at ARYx

New protein farnesyltransferase inhibitors described by Schering-Plough

Recent patent covers synthesis and use of new inhibitors of proinflammatory cytokine production

Novel Takeda compounds claimed for use in heart failure, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...